Revolutionizing Cancer Care: Dr. Tony Ng’s Pioneering Insights at the CCHIO Congress

Revolutionizing Cancer Care: Dr. Tony Ng’s Pioneering Insights at the CCHIO Congress

Dr. Tony Ng, a renowned figure in the field of cancer research, recently participated in the 10-Day HIV-Related Congress. This event was a gathering of top minds in medicine, featuring doctors, scientists, and researchers from over 30 districts in China. Dr. Ng's role as a speaker at this congress highlighted his significant contributions to cancer research and management.
The Role of Artificial Intelligence in Medicine: Insights from an Expert

The Role of Artificial Intelligence in Medicine: Insights from an Expert

In a recent interview, a renowned expert in the field of artificial intelligence (AI) and medicine provides valuable insights into their background, experience, and contributions. The discussion explores the impact of AI in the healthcare industry, the expert's involvement in shaping health reforms in China, their industry experience at IBM, and their role in advising and mentoring startups. This article offers a comprehensive overview of the dialogue, amplifying key points and perspectives shared by Dr. Dimitris Kalogeropoulos.
ESMO Hot Topic Express | Updated Results on Patient Outcomes, Drug Exposure, Safety, and Quality of Life Relevance in the TALAPRO-2 Study

ESMO Hot Topic Express | Updated Results on Patient Outcomes, Drug Exposure, Safety, and Quality of Life Relevance in the TALAPRO-2 Study

In recent years, there have been groundbreaking advancements in the exploration of treatment modalities for prostate cancer, particularly in the use of PARP inhibitors in combination with novel hormonal therapies, offering new hope for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The TALAPRO-2 study has demonstrated that the combination of talazoparib with enzalutamide significantly improves radiographic progression-free survival (rPFS) in the overall mCRPC patient population (HR=0.63; 95% CI, 0.51–0.78; P<0.0001) and in mCRPC patients with homologous recombination repair (HRR) gene defects (HR=0.45; 95% CI, 0.33–0.61; P<0.0001) compared to placebo in combination with enzalutamide[1]. As a result, the combination therapy of talazoparib and enzalutamide received FDA approval on June 20th of this year for first-line use in mCRPC patients with HRR gene mutations.
ESMO 5-Minute Insights | DXd ADCs Shine at ESMO: Professor Jian Zhang Introduces Research in the Field of Breast Cancer

ESMO 5-Minute Insights | DXd ADCs Shine at ESMO: Professor Jian Zhang Introduces Research in the Field of Breast Cancer

ADC drugs, also known as Antibody-Drug Conjugates, combine targeted antibodies with cytotoxic drugs to accurately attack tumor cells and minimize damage to normal cells. In recent years, ADC drugs have made significant breakthroughs in the field of cancer treatment and have become a focus of attention. At this year's ESMO conference, several studies on ADC drugs garnered significant attention. In this report, Professor Jian Zhang from Fudan University-affiliated Cancer Hospital introduces the progress in the treatment of breast cancer using ADC drugs.
The ESMO Congress 2023 has Successfully Concluded, and Ten Major Research Projects Have Bloomed at the Conference!

The ESMO Congress 2023 has Successfully Concluded, and Ten Major Research Projects Have Bloomed at the Conference!

The ESMO Congress 2023, held from October 20th to 24th in Madrid, Spain, has concluded, marking a significant milestone in the field of oncology. With a central theme of "Disseminating innovative research for optimal cancer care," this year's event featured a unique blend of in-person and virtual components, uniting cancer researchers, clinicians, and experts from across the globe. The congress delivered cutting-edge research and unprecedented achievements across various areas of oncology. The notable achievements are particularly eye-catching in five main domains of oncology research, including Lung Cancer, Gynaecological Cancers, Genito-Urinary Cancers, Gastrointestinal Cancers, and Breast Cancer.
ESMO Live Update | Dr. Girard Analyzes PAPILLON: Opening New Doors for First-Line Treatment of EGFR Exon 20 Insertion Mutant Advanced NSCLC

ESMO Live Update | Dr. Girard Analyzes PAPILLON: Opening New Doors for First-Line Treatment of EGFR Exon 20 Insertion Mutant Advanced NSCLC

Based on the results of the PAPILLON trial, presented at the 2023 ESMO Congress, a dual-specificity EGFR/MET monoclonal antibody has the potential to become a standard of care for EGFR exon 20 insertion mutant advanced or metastatic non-small cell lung cancer (NSCLC), although toxicity management must be approached with caution (Abstract LBA5). Dr. Nicolas Girard, the lead author of the study and a researcher at the Curie-Montsouris Thoracic Institute, discussed the implications of these findings for clinical practice in an interview with Oncology Insight conducted during the conference.
ASCO China Voice | Professor Wu Yilong Reports Phase III EVEREST Trial Results at ASCO

ASCO China Voice | Professor Wu Yilong Reports Phase III EVEREST Trial Results at ASCO

The American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago from June 2 to June 6, 2023. Oncology Insight delves into the forefront of the conference, inviting researchers to share the most prominent Chinese research at ASCO, witnessing the advancement of China's anti-tumor efforts on the international stage. Professor Wu Yilong from the People's Hospital of Guangdong Province presented the results of the Phase III EVEREST study at ASCO 2023 in the form of an oral presentation. This article provides specific details of the EVEREST study and invites Professor Wu Yilong to provide an interpretation.
ESMO 2023 | SKB264 (TROP2-ADC) Shows Promise in the Treatment of HR+/HER2- Metastatic Breast Cancer, Advancing in Multiple Cancer Types

ESMO 2023 | SKB264 (TROP2-ADC) Shows Promise in the Treatment of HR+/HER2- Metastatic Breast Cancer, Advancing in Multiple Cancer Types

TROP2 (Trophoblast Cell-Surface Antigen 2) is highly expressed in various solid tumors, making it a hot target in the field of oncology. The development of antibody-drug conjugates (ADCs) targeting this antigen has garnered significant attention. At the 2023 European Society for Medical Oncology (ESMO) Congress held in Madrid, Spain from October 20th to 24th, an innovative TROP2-ADC called SKB264 (MK-2870), jointly developed by CoromboTech and Merck, was presented in an oral report from a phase I/II basket trial for the treatment of advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) (Abstract number: 380MO). The study results confirm that SKB264 exhibits manageable safety and significant anti-tumor activity in HR+/HER2- metastatic breast cancer patients. Professor Yongmei Yin presented the research and its key findings at the conference.